drugset
drugset / Trial / NCT07166081

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Tablets in Non-diabetic Overweight or Obese Adult Subjects

NCT07166081 ↗

Phase 1 Recruiting 80 enrolled BrightGene Bio-Medical Technology Co., Ltd.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a Phase 1, single-center, randomized, placebo-controlled, ascending dose study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), preliminary efficacy, safety and tolerability of BGM0504 following daily oral administrations in non-diabetic overweight or obese adult subjects.

Timeline

Start
2025-08-11
Primary completion
2026-01-12
Completion
2026-05-13

Drugs

EvaluationDrugModalityDoseRoute
Subject BGM0504 Unknown 20 mg Oral
Subject BGM0504 Unknown 40 mg Oral
Subject BGM0504 Unknown 60 mg Oral
Subject BGM0504 Unknown 80 mg Oral

Indications

No indication recorded.